Memphasys Ltd · ASX:MEM
Memphasys — Pitt St Research conference (March 2022)
20 slides from Memphasys's conference presentation, Mar 3, 2022
Slide 1: Creating novel fertility solutions
For personal use only Creating novel fertility solutions March 2022 Alison Coutts Executive Chairman, Memphasys Limited 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is not and does not form part of any To the fullest extent permitted by law, Memphasys and offer, invitation or recommendation in respect of its affiliates and their respective officers, directors, securities. Any decision to buy or sell Memphasys e
Slide 3: Memphasys Investment Proposition
Memphasys Investment Proposition For personal use only Memphasys is a medtech company (ASX: MEM) focused on reproductive biotechnology Developing high value product portfolio (devices, diagnostics and media products) addressing major global human and animal reproductive markets John Aitken, global l
Slide 4: Memphasys Core Product Development Pipeline
Memphasys Core Product Development Pipeline For personal use only Technical Development Addressable Product Initial target use complexity stage market (High/ Low) (POC = proof of concept) Niche Initial sales; 1 Felix device (sperm separator for IVF) High Large Clinical trials “SODA” Large Early; 2 H
Slide 5: Human IVF market
Human IVF market For personal use only Fresh IVF Cycles 5 (Millions) Fresh IVF Cycles (millions) • IVF use is accelerating, but IVF’s success rate remains 4 3.9 3.54 stubbornly low 3 2.68 2.96 3.28 2.46 Average of 2.2 IVF cycles before success, averaged 2.24 • 2 1.85 2.02 for all women <40yo 1 • IVF
Slide 6: Animal Reproduction Market
Animal Reproduction Market For personal use only • Two main methods of reproduction in the livestock industry* : • natural cover • artificial insemination (”AI”) • World wide AI rates** in farmed animals: Dairy cattle 85% Pigs 95% Non-thoroughbred horses 56% • Natural cover is used by many livestock
Slide 7: Felix Device – For Human IVF
1. FelixTM Device – For personal use only For Human IVF The FelixTM is a patented, rapid, easy to use and automated membrane-based electrophoretic device. This separation method offers potential benefits over conventional methods used (Swim- up and Density Gradient Centrifugation (DGC)) by separatin
Slide 8: Advantages of Felix over current processes
Advantages of Felix™ over current processes For personal use only Current sperm separation processes used for IVF • DGC (density gradient centrifugation) and Swim up* • Cost at least ~A$80 (for each technique) per cycle • DGC is more frequently used Felix™ Current processes One step, automated proce
Slide 9: Felix Technology
FelixTM Technology For personal use only Allow ion transfer but block sperm passage Raw Processed semen sperm Mature, negatively charged sperm harvested after 6 minutes Separates sperm from other cell types 9
Slide 10: Importance of sperm's negative charge
Importance of sperm’s For personal use only negative charge • During sperm maturation, the sperm head is covered by a glycoprotein and glycolipid coating which has a highly negative electric charge • Negative charge has been correlated with: • Normal morphology (shape) • Lower levels of DNA fragment
Slide 11: Felix device commercialisation progress
Felix™ device commercialisation progress For personal use only • KOL in vitro testing (results to be published) • 15 global KOLs testing; completion expected first half 2022; • Results showing FelixTM handles the widest range of semen samples and selects sperm with less DNA damage than the DGC proce
Slide 12: Felix Device Pathway to Market
Felix™ Device Pathway to Market For personal use only • Initial focus is on building sales in four selected countries with low regulatory barriers for Felix: Country Fresh IVF Expected % growth KOL % of global Cycles in fresh IVF rate engaged in market3 2018 cycles by market 2026 Japan 269,110 699,1
Slide 13: The "SODA" oxidative stress diagnostic
2. The “SODA” oxidative stress diagnostic For personal use only • Oxidative stress occurs when there is an imbalance of reactive oxygen species production (primarily from metabolism*) and the body’s ability to counter the adverse effects of these products • Oxidative stress is pervasive in many seri
Slide 14: Need for oxidative stress diagnostic
Need for oxidative stress diagnostic For personal use only • It is important to determine if, where, and how much, oxidative stress is present • Determining whether the oxidative stress is local or systemic will indicate the treatment required • Providing powerful antioxidants when no or little oxid
Slide 15: The "SAMSON" device: two potential products
3. The “SAMSON” device: two potential products For personal use only Equine pregnancy predictor • Developing a rapid onsite in-vitro diagnostic test to assess stallion semen for probability of successful mare pregnancy. • For thoroughbred and non-thoroughbred (eg standardbred) horses • High variabil
Slide 16: The "SEMPORT" semen long life storage & transport device
3. The “SEMPORT” semen long life storage & transport device For personal use only For comprehensive human semen diagnostic from remote donor • Normally semen is frozen if transported over long distances and this severely affects diagnostic accuracy • Product maintained at ambient temperature for up
Slide 17: Cryopreservation projects
5. Cryopreservation projects For personal use only Felix™ device use with cryopreserved semen/ sperm • Cryopreserving (freezing) is frequently used • for donor sperm, sperm retrieved from testicular biopsies, poor quality samples* and from men who cannot provide sperm to coincide with the IVF proced
Slide 18: Corporate Snapshot
Corporate Snapshot For personal use only Board of Directors Alison Coutts – Executive Chairman ASX Code MEM Extensive experience across a number of industry sectors and disciplines including international Share price (as at 14/02/22) $0.063 engineering project management with Bechtel Corporation in
Slide 19: Memphasys Investment Highlights
Memphasys Investment Highlights For personal use only Addressing major global human and animal reproductive markets First commercial sales of FelixTM device Key collaborations with University of Newcastle research team, led by Global Fertility Expert, Professor John Aitken and Clinical industry part
Slide 20: Thank you
For personal use only Thank you Alison Coutts Executive Chairman, Memphasys Ltd 30-32 Richmond Rd, Homebush NSW 2140 Australia Phone: +612 8415 7300 20